دورية أكاديمية
New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.
العنوان: | New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization. |
---|---|
المؤلفون: | Mohammed HHH; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt., Abd El-Hafeez AA; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.; Cancer Biology Department, Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt., Ebeid K; Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Manufacturing, Deraya University, New Minia City, Minia, Egypt., Mekkawy AI; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Sohag University, Sohag, Egypt., Abourehab MAS; Department of Pharmaceutics, Faculty of Pharmacy, Umm Al Qura University, Makkah, Saudi Arabia., Wafa EI; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Alhaj-Suliman SO; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Salem AK; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA., Ghosh P; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.; Department of Medicine, University of California San Diego, La Jolla, CA, USA.; Rebecca and John Moore Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA.; Veterans Affairs Medical Center, La Jolla, CA, USA., Abuo-Rahma GEA; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt., Hayallah AM; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Sphinx University, New Assiut, Egypt., Abbas SH; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt. |
المصدر: | Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 1346-1363. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Basingstoke, UK : Taylor & Francis, c2002- |
مواضيع طبية MeSH: | Antineoplastic Agents*/metabolism , Antineoplastic Agents*/pharmacology , Chalcone*/pharmacology , Chalcones*/metabolism , Chalcones*/pharmacology, Caco-2 Cells ; Cell Line, Tumor ; Cell Proliferation ; Ciprofloxacin/pharmacology ; DNA Damage ; DNA Topoisomerases, Type I/metabolism ; DNA Topoisomerases, Type II/metabolism ; Doxorubicin/pharmacology ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Polymerization ; Structure-Activity Relationship ; Triazoles/pharmacology ; Tubulin/metabolism |
مستخلص: | A series of novel 1,2,3-triazole-linked ciprofloxacin-chalcones 4a-j were synthesised as potential anticancer agents. Hybrids 4a-j exhibited remarkable anti-proliferative activity against colon cancer cells. Compounds 4a-j displayed IC |
References: | Eur J Med Chem. 2014 Oct 6;85:758-77. (PMID: 25137491) J Med Chem. 2005 Oct 20;48(21):6523-43. (PMID: 16220969) Drug Discov Today. 2017 Oct;22(10):1572-1581. (PMID: 28676407) Eur J Med Chem. 2019 May 15;170:173-194. (PMID: 30897396) Arch Pharm (Weinheim). 2019 Jul;352(7):e1800376. (PMID: 31215674) Curr Med Chem Anticancer Agents. 2003 Nov;3(6):439-50. (PMID: 14529452) Science. 2013 Apr 26;340(6131):457-60. (PMID: 23558174) Eur J Med Chem. 2020 Mar 1;189:112062. (PMID: 31986406) Eur J Cancer. 1991;27(7):897-900. (PMID: 1834124) Eur J Med Chem. 2011 Dec;46(12):6025-38. (PMID: 22036229) Biomed Pharmacother. 2009 Mar;63(3):216-20. (PMID: 18328669) Drug Discov Today. 2007 Jan;12(1-2):34-42. (PMID: 17198971) Eur J Med Chem. 2020 Dec 15;208:112756. (PMID: 32942186) Invest New Drugs. 2019 Aug;37(4):784-790. (PMID: 30740631) Antimicrob Agents Chemother. 1994 Jan;38(1):130-3. (PMID: 8141566) Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40. (PMID: 12042765) Curr Med Chem. 2019;26(17):3132-3149. (PMID: 29446718) Eur J Med Chem. 2013 Nov;69:427-38. (PMID: 24090914) Biochem Cell Biol. 2017 Jun;95(3):379-384. (PMID: 28177759) Eur J Cancer. 1993;29A(3):395-9. (PMID: 8398340) Curr Clin Pharmacol. 2010 Feb;5(1):1-29. (PMID: 19891604) Eur J Med Chem. 2018 May 10;151:705-722. (PMID: 29660690) Bioorg Chem. 2017 Apr;71:30-54. (PMID: 28126288) BMC Cancer. 2015 Aug 11;15:581. (PMID: 26260159) Eur J Med Chem. 2017 Jan 5;125:143-189. (PMID: 27662031) In Vitro Cell Dev Biol Anim. 2015 Jan;51(1):92-101. (PMID: 25148824) J Enzyme Inhib Med Chem. 2016 Oct;31(5):796-809. (PMID: 26226179) J Med Chem. 2019 Jan 24;62(2):420-444. (PMID: 30035545) Eur J Med Chem. 2018 Jul 15;155:772-781. (PMID: 29945100) Biomed Pharmacother. 2005 Oct;59(9):501-10. (PMID: 16263236) Biochemistry. 1989 May 2;28(9):3879-85. (PMID: 2546584) Anticancer Agents Med Chem. 2018;18(1):21-37. (PMID: 27528183) Chem Biol Drug Des. 2015 Oct;86(4):410-23. (PMID: 25643871) Bioorg Chem. 2017 Dec;75:86-98. (PMID: 28922629) Eur J Med Chem. 2018 May 10;151:339-350. (PMID: 29635166) Annu Rev Biochem. 2001;70:369-413. (PMID: 11395412) J Toxicol. 2016;2016:7651047. (PMID: 26880913) Adv Exp Med Biol. 2012;732:1-8. (PMID: 22210248) J Biol Chem. 1997 Jul 4;272(27):17118-25. (PMID: 9202030) Molecules. 2015 Jan 14;20(1):1357-76. (PMID: 25594346) Eur J Med Chem. 2018 Jan 1;143:1277-1300. (PMID: 29126724) Biomed Pharmacother. 2019 Mar;111:934-946. (PMID: 30841473) Eur J Med Chem. 2019 Mar 15;166:206-223. (PMID: 30711831) Eur J Med Chem. 2020 Feb 1;187:111970. (PMID: 31881454) Bioorg Chem. 2021 Jan;106:104422. (PMID: 33248713) Eur J Pharm Sci. 2021 Jan 1;156:105594. (PMID: 33059042) Eur J Med Chem. 2021 Jan 1;209:112904. (PMID: 33077264) Eur J Med Chem. 2012 Jan;47(1):615-8. (PMID: 22093760) Curr Opin Microbiol. 1999 Oct;2(5):504-8. (PMID: 10508721) Bioorg Med Chem. 2009 Aug 1;17(15):5396-407. (PMID: 19595598) Bioorg Chem. 2020 Jan;95:103565. (PMID: 31927336) Eur J Med Chem. 2005 Apr;40(4):361-9. (PMID: 15804535) Bioorg Med Chem. 2018 Aug 7;26(14):3958-3966. (PMID: 29954683) Arch Pharm (Weinheim). 2022 Jan;355(1):e2100158. (PMID: 34559414) J Med Chem. 2014 Oct 9;57(19):7874-87. (PMID: 24946140) J Vis Exp. 2017 Nov 3;(129):. (PMID: 29155797) Int Immunopharmacol. 2011 Mar;11(3):295-309. (PMID: 21184860) Eur J Med Chem. 2017 Sep 29;138:501-513. (PMID: 28692915) Eur J Med Chem. 2019 Apr 15;168:357-372. (PMID: 30826511) Biochem Pharmacol. 2008 Mar 15;75(6):1272-81. (PMID: 18191106) Molecules. 2022 Jan 25;27(3):. (PMID: 35164037) Bioorg Chem. 2019 Mar;84:150-163. (PMID: 30502626) Int J Pharm. 2021 Sep 5;606:120876. (PMID: 34252520) Bioorg Med Chem. 2016 Oct 1;24(19):4636-4646. (PMID: 27555286) Transl Oncol. 2021 Oct;14(10):101174. (PMID: 34243011) Eur J Med Chem. 2018 Oct 5;158:917-936. (PMID: 30261467) Evid Based Complement Alternat Med. 2013;2013:815621. (PMID: 23690855) Bioorg Med Chem Lett. 2013 Dec 1;23(23):6292-5. (PMID: 24138941) Bioorg Med Chem Lett. 2020 Dec 1;30(23):127610. (PMID: 33045329) Eur J Med Chem. 2019 Dec 1;183:111700. (PMID: 31546197) Expert Opin Ther Pat. 2017 Apr;27(4):415-426. (PMID: 27897041) |
معلومات مُعتمدة: | P30 ES005605 United States ES NIEHS NIH HHS |
فهرسة مساهمة: | Keywords: Click synthesis; DNA damage; HCT116 cells; chalcone; ciprofloxacin; cytotoxicity; topoisomerase I and II inhibitors; tubulin polymerisation inhibition |
المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Chalcones) 0 (Triazoles) 0 (Tubulin) 5E8K9I0O4U (Ciprofloxacin) 5S5A2Q39HX (Chalcone) 80168379AG (Doxorubicin) EC 5.99.1.2 (DNA Topoisomerases, Type I) EC 5.99.1.3 (DNA Topoisomerases, Type II) |
تواريخ الأحداث: | Date Created: 20220513 Date Completed: 20220517 Latest Revision: 20220907 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC9116245 |
DOI: | 10.1080/14756366.2022.2072308 |
PMID: | 35548854 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1475-6374 |
---|---|
DOI: | 10.1080/14756366.2022.2072308 |